Genomics in Drug Discovery and Development (PDF)
(Sprache: Englisch)
Early characterization of toxicity and efficacy would significantly
impact the overall productivity of pharmaceutical R&D and
reduce drug candidate attrition and failure. By describing the
available platforms and weighing their relative advantages...
impact the overall productivity of pharmaceutical R&D and
reduce drug candidate attrition and failure. By describing the
available platforms and weighing their relative advantages...
sofort als Download lieferbar
eBook (pdf)
141.99 €
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
Produktdetails
Produktinformationen zu „Genomics in Drug Discovery and Development (PDF)“
Early characterization of toxicity and efficacy would significantly
impact the overall productivity of pharmaceutical R&D and
reduce drug candidate attrition and failure. By describing the
available platforms and weighing their relative advantages and
disadvantages, including microarray data analysis, Genomics in Drug
Discovery and Development introduces readers to the biomarker,
pharmacogenomic, and toxicogenomics toolbox. The authors provide a
valuable resource for pharmaceutical discovery scientists,
preclinical drug safety department personnel, regulatory personnel,
discovery toxicologists, and safety scientists, drug development
professionals, and pharmaceutical scientists.
impact the overall productivity of pharmaceutical R&D and
reduce drug candidate attrition and failure. By describing the
available platforms and weighing their relative advantages and
disadvantages, including microarray data analysis, Genomics in Drug
Discovery and Development introduces readers to the biomarker,
pharmacogenomic, and toxicogenomics toolbox. The authors provide a
valuable resource for pharmaceutical discovery scientists,
preclinical drug safety department personnel, regulatory personnel,
discovery toxicologists, and safety scientists, drug development
professionals, and pharmaceutical scientists.
Autoren-Porträt von Dimitri Semizarov, Eric Blomme
Dimitri Semizarov, PhD, is a Senior Group Leader in theCancer Research Department of Abbott Laboratories' Global
Pharmaceutical R&D. Dr. Semizarov leads cancer genomics
research at Abbott, applying genomics technologies to enable
personalization of cancer therapy. He is author or coauthor of more
than twenty scientific articles and eight patent applications, as
well as three book chapters (including two chapters in Wiley's
Preclinical Development Handbook).
Eric Blomme, DVM, PhD, Diplomate, American College of
Veterinary Pathologists, is a Senior Project Leader for Cellular,
Molecular, and Exploratory Toxicology in Global Pharmaceutical
R&D at Abbott Laboratories. He has extensive drug discovery,
toxicology, and screening experience working for Abbott, Pharmacia,
Monsanto, Searle, Ohio State University, and Cornell University.
Dr. Blomme has written over fifty journal articles and eight book
chapters, and is a reviewer for multiple scientific journals in the
fields of toxicology and pathology.
Bibliographische Angaben
- Autoren: Dimitri Semizarov , Eric Blomme
- 2008, 1. Auflage, 480 Seiten, Englisch
- Verlag: John Wiley & Sons
- ISBN-10: 0470409762
- ISBN-13: 9780470409763
- Erscheinungsdatum: 11.11.2008
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
eBook Informationen
- Dateiformat: PDF
- Größe: 5.13 MB
- Mit Kopierschutz
Sprache:
Englisch
Kopierschutz
Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.
Kommentar zu "Genomics in Drug Discovery and Development"
0 Gebrauchte Artikel zu „Genomics in Drug Discovery and Development“
| Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
|---|
Schreiben Sie einen Kommentar zu "Genomics in Drug Discovery and Development".
Kommentar verfassen